IMMUCELL CORP /DE/

Regulatory Filings • Mar 20, 2014

8-K 1 immucell8k.htm IMMUCELL CORPORATION 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

| Date of Report: March 19, 2014 (Date of earliest event reported) | | |
| --- | --- | --- |
| ImmuCell Corporation (Exact name of registrant as specified in its charter) | | |
| DE (State or other jurisdiction of incorporation) | 001-12934 (Commission File Number) | 01-0382980 (IRS Employer Identification Number) |
| 56 Evergreen Drive, Portland, Maine (Address of principal executive offices) | | 04103 (Zip Code) |
| 207-878-2770 (Registrant's telephone number, including area code) | | |
| Not Applicable (Former Name or Former Address, if changed since last report) | | |

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers On March 19, 2014, Mr. Paul R. Wainman was appointed to serve as a member of the Company's Board of Directors, effective March 31, 2014. Mr. Wainman will serve as Chair of the Company's Audit Committee and qualifies as a "financial expert" in accordance with SEC regulations. Item 9.01. Financial Statements and Exhibits (d) Exhibits 99.1 Press Release of ImmuCell Corporation dated March 20, 2014 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 20, 2014 IMMUCELL CORPORATION By: /s/ Michael F. Brigham Michael F. Brigham President and CEO

Exhibit Index
Exhibit No.	Description
99.1	Press Release of ImmuCell Corporation dated March 20, 2014